ABSTRACT
Description: Optisulin is a long-acting human insulin analogue. It is apparently identical to the product marketed with the trade name Lantus. It differs from the human insulin at the C-terminal end of the B chain, which is elongated by two arginine residues, and at the C terminus of the A chain, where an asparagine is replaced by a glycine. Optisulin is produced in modified Escherichia coli by recombinant DNA technology and is presented as a solution for subcutaneous injection.
